Rating Change
Morgan Stanley reiterated its Overweight rating on Belite Bio, Inc (NASDAQ:BLTE) on August 14, 2026.
reiterateNASDAQ:BLTE
Morgan Stanley Reiterates Overweight Rating on Belite Bio, Inc (BLTE)
Morgan Stanley reiterated its Overweight rating on Belite Bio, Inc (NASDAQ:BLTE) on August 14, 2026.
At publication ·
What changed
Belite Bio, Inc (NASDAQ:BLTE) · reiterate
- Firm
- Morgan Stanley
- Rating
- Overweight to Overweight
- Price at event
- $162.80
- Market capitalization
- $5.2B
At a glance
Key takeaways
- Morgan Stanley reiterated an Overweight rating on Belite Bio (BLTE) on August 14, 2026, with the stock trading at $162.80 and a market capitalization of $5.2 billion.
Market Context
Belite Bio, Inc operates in the Healthcare sector. The stock currently trades at $162.80 with a market capitalization of $5.2B.
Analyst coverage from Morgan Stanley provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Belite Bio, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Belite Bio, Inc
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 14, 2026 | Morgan Stanley | Overweight | N/A |
| Aug 14, 2026 | Cantor Fitzgerald | Overweight | N/A |
| Aug 12, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jun 15, 2026 | HC Wainwright & Co. | Buy | N/A |
| May 26, 2026 | Mizuho | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View BLTE Stock Page
Frequently Asked Questions
What does the Overweight rating mean for BLTE?
A rating of Overweight from Morgan Stanley reflects the analyst's outlook on Belite Bio, Inc (NASDAQ:BLTE). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the BLTE forecast page.